Engagement of the activating receptor NKG2D (natural killer group 2 member D) with its ligands (NKG2DL) major histocompatibility complex class I related-A and -B (MICA/B), UL-16 binding protein families (ULBPs 1-6) is important to ensure the innate immunity to tumor cells. However, these cells have developed strategies to downregulate NKG2DL expression and avoid immune recognition. We demonstrate that DNA methylation can contribute to the absence of NKG2DL expression during tumor progression. We analyzed the DNA methylation profiles for each NKG2DL by pyrosequencing in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), hepatocellular carcinoma (HC), breast cancer and colon cancer cell lines. High levels of DNA methylation for NKG2DL were found in some tumor cell lines, mainly in AML cells. This hypermethylation was correlated with the absence of transcription for NKG2DL. Higher DNA methylation levels for MICA, ULBP1 and ULBP2 were observed in AML patients (n = 60) compared with healthy donors (n = 25). However, no DNA methylation for NKG2DL was found in colon cancer patients (n = 44). Treatment with demethylating agents (5-azacytidine and 5-aza-2'-deoxycytidine) restored the expression of NKG2DL on the cell surface of AML cells, leading to an enhanced recognition by NKG2D-expressing cells. Our data suggest that NKG2DL may be aberrantly silenced by DNA methylation as a consequence of tumor development in AML patients. 6 CL-L and BS-A share senior authorship.
INTRODUCTION
Natural killer (NK) cells are components of the innate immune system that have an important role in antitumor immunity to tumor cells. 1 NK cell-mediated cytotoxicity is regulated by a tight balance between inhibiting and activating receptors that recognize ligands expressed on the surface of tumor cells. One of these activating receptors is the NK group 2 member D (NKG2D), which is mainly expressed in NK, NKT, γδT and αβ CD8 + T cells. 2 NKG2D recognizes different ligands in humans: major histocompatibility complex class I related-A and -B (MICA and MICB) and UL-16 binding protein families (ULBPs 1-6). 3, 4 Under physiological conditions, the expression of NKG2D ligands (NKG2DLs) is absent or present at very low levels in most cell types. Nevertheless, during cancer development, the activation of the DNA damage pathway (ATM/ATR pathway), transcription factors such as nuclear factor-κB or several oncogenes (BCR/ABL, c-myc, p53 and so on) can enhance NKG2DL expression on the cell surface, making tumor cells susceptible to recognition and killing by NKG2Dpositive cells. [5] [6] [7] [8] Malignant cells have developed diverse strategies to avoid NKG2D-mediated immune recognition. One of the most widely studied mechanisms is the shedding of NKG2DL, which consists of the release of soluble NKG2DL from the cell surface of tumor cells by proteolytic cleavage. These soluble molecules are able to bind to the NKG2D receptor and induce their endocytosis, thereby impairing responsiveness to tumor cytolysis. [9] [10] [11] Several metalloproteinases (matrix metalloproteinases and a disintigrin and metalloproteinase families) are involved in shedding MICA, MICB or ULBP2, whereas ULBP3 is released from the cell surface, especially in exosomes. [12] [13] [14] [15] [16] [17] Additional mechanisms, such as the presence of endoplasmic reticulum proteins (ERp5 and GRP78), which are involved in the protein folding or the palmitoylation of MICA that enables the recruitment to detergent-resistant membranes, are also involved in MICA shedding. [18] [19] [20] Release of NKG2DL from the cell surface of tumor cells has been used in the diagnosis and prognosis of several malignancies. 21 Current antitumor therapy studies tend to focus on increasing NKG2DL expression in cancer cells to enhance their susceptibility to lysis mediated by NKG2D-positive cytotoxic cells. Azacytidine (5-azacytidine (5azaC)) and decitabine (5-aza-2'-deoxycytidine (DAC)) are DNA methyltransferase (DNMT) inhibitors (DNMTi) currently used to treat patients with myelodysplastic syndromes and acute myeloid leukemia (AML). 22 Previous studies in cell lines showed that both reagents enhance the cell surface expression of NKG2DL, alone or in combination with differentiation-promoting agents in tumor cells. [23] [24] [25] Moreover, combined treatment with histone deacetylase inhibitors, not only induce NKG2DL expression but also blocks the release of soluble NKG2DL in several types of cancer cell. [26] [27] [28] [29] [30] [31] [32] [33] [34] All these observations suggest that NKG2DL expression may be regulated by chromatin remodeling in tumor cells. In fact, high levels of ULBP2 expression were found in defective DNMTs colon cancer cells suggesting that this ligand could be regulated by DNA methylation. 35 However, an in-depth study of the DNA methylation profile for NKG2DL regulation has not yet been performed.
In this study, we demonstrate that promoter regions of NKG2DL are aberrantly methylated in tumor cell lines, mainly in AML cell lines. In primary samples from AML patients, MICA, ULBP1 and ULBP2 DNA methylation levels are significantly higher than in healthy donors. However, all NKG2DL were found to be hypomethylated in colon cancer patients. Treatment of tumor cells with hypomethylating reagents (5azaC and DAC) increases NKG2DL expression on the cell surface, making them more susceptible to recognition and lysis by NKG2D-mediated NK cells.
RESULTS

NKG2DL expression is highly heterogeneous in hematological and solid tumor cells
We studied the expression profile of each NKG2DL (MICA, MICB, ULBP1, ULBP2 and ULBP3) by quantitative real-time PCR in several human cell lines derived from hematological (AML and acute lymphocytic leukemia (ALL)) and solid tumors (hepatocellular carcinoma (HCC), breast and colon). We observed that NKG2DL expression was highly heterogeneous among cell lines (Figure 1a ). MICA and MICB transcripts were detected in most cell lines, although at different levels. ULBP expression was more restricted, mainly in the case of ULBP3, except in colon cancer cell lines, in which high levels of transcription for this ligand were found. At least one ligand was expressed in all cell lines. However, depending on their origin, the frequencies of the combined expression of two or more NKG2DL in cancer cell lines differed ( Figure 1b ). So, although all solid tumor (HCC, breast cancer and colon cancer) cell lines expressed two or more NKG2DL, their combined expression was less frequent in hematological cells. More than 25% of AML and ALL cell lines only expressed MICB, implying that the absence of one or more ligands is a common characteristic of hematological tumor cells. Hypermethylation of MICA, ULBPs 1-3 genes is associated with the absence of transcription In view of these findings, we postulated that epigenetic mechanisms such as DNA methylation could contribute to the lack of NKG2DL expression in tumor cells. For this reason, we analyzed DNA methylation patterns by the bisulfitesequencing method. We selected a regulatory region around the transcription start site that contained 23 CpGs sites located from − 453 to − 53 bp for MICA, 30 CpGs (−339 to +94 bp) for MICB, 34 CpGs (−493 to − 88 bp) for ULBP1, 18 CpGs (−246 to − 15 bp) for ULBP2 and finally, 38 CpGs (−222 to +174 bp) for ULBP3 ( Figure 2 ).
Firstly, to study whether changes in the DNA methylation level could involve changes in expression level, we examined two cell lines with different transcription levels for each NKG2DL. High levels of DNA methylation were detected in cell lines lacking NKG2DL transcription (MICA, ULBP2 and ULBP3 in HL60 cells, and ULBP1 in NB4 cells). In contrast, and as expected, cell lines with high levels of transcription for these ligands were completely unmethylated (MICA and ULBP2 in HEL-R cells, ULBP1 in MOLM-13 cells and ULBP3 in MV4;11 cells). For MICB, we assayed two cell lines with differing transcription levels (HEL-R and HL60). A close correlation between methylation and transcription levels for this gene was not found, suggesting that MICB expression is not regulated by DNA methylation.
Consistent with these results, we determined the specific DNA methylation level for MICA, MICB and ULBPs 1-3 genes in all cell lines by bisulfite pyrosequencing. This technique enables rapid and straightforward quantification of DNA methylation. All NKG2DL were highly methylated (460%) in at least one cell line: MICA in HL60 and KG1A cell lines, ULBP1 in NB4 and RS411, ULBP2 in HL60, and ULBP3 in HL60, NB4 and CAMA-1 cells (Table 1) . Moreover, high DNA methylation levels were closely associated with a lack of transcription for MICA, ULBP1, ULBP2 and ULBP3 ligands in these cells. However, only partial DNA methylation (35-60%) of MICB was observed in KG1A, NB4, HEL-R and HT29 cell lines. Thus, our results imply that DNA methylation may contribute to the lack of expression of NKG2DL in tumor cells.
NKG2DL are methylated in primary AML but not in colon cancer samples To determine whether the NKG2DL methylation pattern observed in AML cell lines is similar in primary AML samples, we quantified the DNA methylation levels for NKG2DL in peripheral blood lymphocytes (PBLs) isolated from AML patients (n = 60) using the bisulfite pyrosequencing technique. All PBLs samples from AML patients showed ⩾ 70% myeloid blasts. As controls, we used PBLs isolated from healthy donors (n = 25). To establish the appropriate control sub-population, we analyzed the expression and methylation pattern for each NKG2DL in the cell sub-populations isolated Figure 2 . Different DNA methylation patterns for NKG2DL with respect to transcription levels. The DNA methylation patterns of NKG2DL (MICA, MICB, ULBP1, ULBP2 and ULBP3) genes were analyzed by bisulfite sequencing. Diagrams illustrate the genomic region surrounding the transcriptional start site (TSS, thick arrow) analyzed in each NKG2DL. The thin vertical line indicates CpG positions. Bisulfite-sequencing and pyrosequencing primers are shown by dashed and dotted lines, respectively. The DNA methylation profile for each NKG2DL was determined in two tumor cell lines with different levels of expression for these ligands by bisulfite sequencing. Ten individual clones were sequenced for each cell line. Open and filled circles represent unmethylated and methylated CpGs, respectively. from peripheral blood (monocytes, lymphocytes and granulocytes) ( Figure 3 ). Monocytes and granulocytes had different NKG2DL expression levels in healthy donors, whereas all lymphocytes lacked NKG2DL expression. However, NKG2DL were fully demethylated in all cell types, and unmethylated in subsets of CD4+ and CD8+ T lymphocytes, B cells and NK cells (results not shown). Therefore, we concluded that PBLs from healthy controls are an appropriate control population because all NKG2DL are unmethylated independently of the expression. Thus, the presence of DNA methylation for NKG2DL in AML patients can only be due to tumor cells.
Quantification of DNA methylation for each NKG2DL showed that all ligands were more strongly methylated in AML patients compared with healthy controls (Figure 4a ). The percentage DNA methylation levels for MICA, ULBP1 and ULBP2 were significantly higher in AML patients than in healthy controls (MICA: 6.13 ± 9.02% vs 0.89 ± 0.16%; ULBP1: 7.06 ± 6.98% vs 1.96 ± 0.38%; ULBP2: 31.65 ± 24.97% vs 3.34 ± 2.28%; P o 0.001). DNA methylation of MICB and ULBP3 was also higher in AML patients, although the difference was not statistically significant. We found no significant differences in comparisons of the DNA methylation levels of NKG2DL in 44 paired normal and tumor tissues from colon cancer patients. NKG2DL were unmethylated in all tumor samples according to the results previously found in colon cancer cell lines.
In AML patients, an aberrant DNA hypermethylation level of NKG2DL was defined as that for levels higher than the median ± s.d. Accordingly, the established density cutoffs were 12.5% for MICA, 11% for MICB and ULBP1, 54% for ULBP2 and 12% for ULBP3. 59% of patients showed hypermethylation of at least one NKG2DL, the combination of methylated ligands varying considerably between patients ( Figure 4b ). No statistically significant association of NKG2DL methylation levels with age, sex, French-American-British classification, FLT3 or NPM1 mutations or treatment response was found. We conclude that NKG2DL are highly methylated in AML patients and that this aberrant DNA methylation pattern could be acquired during disease progression.
Increased NKG2DL expression after treatment with 5azaC and DAC hypomethylating agents
To verify the role of DNA methylation in the absence of NKG2DL expression, we examined whether the induced demethylation of MICA, ULBP1, ULBP2 and ULBP3 genes by DNMTi could enhance NKG2DL expression. To this end, we chose the AML (HL60, NB4 and KG1A), ALL (RS411) and breast cancer (CAMA-1) cell lines, which showed hypermethylation (460%) of some NKG2DL. Beforehand, we determined the appropriate concentration of DNMTi that did not compromise the viability of each cell type (data not shown). Cells were treated with 5azaC and DAC for 72 h and the NKG2DL expression was then analyzed by real-time-PCR and flow cytometry.
After treatment with both DNMTi, a significant increase in NKG2DL transcription was observed in all cell lines. ULBP2 was the ligand most susceptible to demethylation, resulting in up to a 400fold induction in the HL60 cell line after DAC treatment (Figure 5a ). NKG2DL expression was also induced on the cell surface of AML cells (HL60, KG1A and NB4) ( Figure 5b ). However, no changes in ULBP1 and ULBP3 expression were found on the cell surface of RS411 and CAMA-1 cell lines after DNMTi treatment, suggesting that DNA methylation has an important role in regulating NKG2DL in AML but not in other tumors types.
This result confirms that NKG2DL are regulated by DNA methylation in AML cells and therefore that treatment with demethylating agents may increase NKG2DL expression at the cell surface, thereby facilitating immune recognition.
Treatment of tumor cells with 5azaC and DAC increases NKG2Dmediated cytotoxicity
The engagement of NKG2D-NKG2DL activates the effector functions of cytotoxic NK cells, leading to the release of cytotoxic granules and the lysis of tumor cells. Therefore, we examined whether the increased expression of NKG2DL after treatment with DNMTi agents could enhance the recognition and lysis mediated by NK cells. For this purpose, we used a well-known model that enables the NKG2D-NKG2DL interaction to be specifically analyzed. The NKL cell line, which expresses high levels of NKG2D, was used as a source of effector cells. As target cells, we used the HL60, KG1A and NB4 tumor cell lines before and after DNMTi treatment. As shown in Figure 6a , the percentage of specific lysis of tumor cells before treatment was very low because of the lack of NKG2DL. However, when tumor cells were previously incubated with demethylating agents for 72 h and then co-cultured with effector cells, the percentage of specific lysis was significantly higher for all analyzed effector:target (E:T) ratios.
This increase in cytotoxicity was critically dependent on the NKG2D-NKG2DL interaction, because when NKL cells were incubated beforehand with anti-NKG2D blocking monoclonal antibody (mAb) for 1 h, the percentage of specific lysis was significantly lower for all E:T ratios (Figures 6a). Some differences between the treatments with 5azaC and DAC were noted. Although the cytotoxic capacity was greater after treatment with 5azaC in HL60 and KG1A cells, a more pronounced effect of DAC in NB4 cell lines was observed. Consistent with the effects on lytic ability by demethylating agents, we also analyzed the interferon-γ (IFN-γ) production after 5azaC and DAC treatments. As a positive control, we used the HEL-R cell line that expresses high levels of all NKG2DL on the cell surface. Figure 6b shows that the positive cell line produces IFN-γ in a NKG2D-dependent manner. However, IFN-γ was also produced by methylated cell lines (HL60, KG1A and NB4). In spite of the elevated IFN-γ levels in these cells, we observed that treatment with DAC reduced the IFN-γ production in a NKG2D-dependent manner, while in control cells (treated with dimethylsulphoxide) or after 5azaC treatment this effect was not observed. Taken together, our data corroborate that treatment of AML cells with demethylating agents increases NKG2DL expression enhancing the recognition and lysis of these tumor cells by NKL cells.
Methylated NKG2DL impair the recognition of AML cells by NK and CD8+ T cells Finally, we attempted to confirm whether DNA methylation for NKG2DL impairs the recognition of AML cell lines by cytotoxic NK and CD8+ T cells. To this end, we quantified CD107a degranulation in isolated CD8+ T and NK cells from healthy donors against unmethylated-NKG2DL cells (HEL-R) and methylated-NKG2DL cell lines (NB4, KG1A and HL60).
We observed some controversies in the degranulation of polyclonal NK (pNK) cells against AML cell lines. Although some donors showed more degranulation in HEL-R than in methylated-NKG2DL cell lines (responders donors by NKG2D, pNK#1 and pNK#2), others NKs from different donors act inversely (nonresponders donors by NKG2D, pNK#3 and pNK#4) ( Figure 7a ). This result could be due to the different expression profiles of activating and inhibitory receptors in NK cells isolated from different healthy donors. To corroborate this, we analyzed the expression of some ligands for these activating and inhibitory receptors expressed on AML cell lines (Figure 7b and Supplementary Figure 1 ). A clear difference was observed for the expression levels of human leukocyte antigen (HLA)-class I (HLA-I) and CD48 (2B4 ligand) molecules. The NKG2DL-positive HEL-R cell line expresses high levels of HLA-I and low levels of CD48, whereas methylated-NKG2DL AML cell lines showed low HLA-I expression and high expression of the activation-inducing CD48 ligand. In fact, when we blockaded the NKG2A inhibitory receptor in NK cells from a non-responder donor against HEL-R (pNK#4) with an anti-NKG2A mAb, a significant increase in the percentage of CD107a + cells was observed (Figure 7c ). Moreover, Figure 3 . Expression and DNA methylation patterns for NKG2DL in cell subsets isolated from healthy controls. Monocytes (Mo), PBLs (Lymph) and polymorphonuclear cells (PMNs) were isolated from peripheral blood of six healthy donors. NKG2DL expression on the cell surface was measured for each cell type (gray markers) by flow cytometry using anti-human MICA, MICB, ULBP1, ULBP2 and ULBP3 mAbs, followed by incubation with a FITC-conjugated goat anti-mouse immunoglobulin G. Surface expression was determined as specific fluorescence index (SFI) (mean specific fluorescence intensity: mean fluorescence of respective specific mAbs/mean fluorescence of secondary antibody). Black histograms show the DNA methylation level for each NKG2DL assayed by pyrosequencing. The level of methylation was expressed as an average percentage of total CpGs analyzed for each NKG2DL.
this increase was dependent of NKG2D as it is shown by the reduced degranulation of NK cells after combined incubation with anti-NKG2A and anti-NKG2D mAb. That data suggest that blockage of the inhibitory signaling could favor the elimination of AML cells in a NKG2D-dependent manner. In addition, we analyzed whether the enhanced degranulation of NK cells after co-culture with methylated-NKG2DL cell lines could be due to the high expression of the CD48 ligand. After blockage with an anti-2B4 mAb, a slight reduction of the percentage of CD107a + cells was observed in KG1A and HL60 cell lines but it did not reach statistical significance (Figure 7c ).
However, when NK cells from a responder donor (pNK#2) were analyzed, a clear impaired degranulation was shown after NKG2D blockage in the HEL-R cell line but remains unchanged in the methylated-NKG2DL AML cell lines (Figure 7c) . Similar results were observed with activated CD8+ T lymphocytes, where a higher percentage of CD107a+ cells after co-cultures with NKG2DLpositive AML cell lines than with NKG2DL-negative cells was shown (Figure 7d ). This degranulation of CD8+ T cells was significantly dependent of the NKG2D-NKG2DL interaction, suggesting that high levels of NKG2DL expression in AML cells lead to an enhanced recognition of CD8+ T cells.
In other word, our findings confirm that aberrant DNA methylation of NKG2DL in AML cells impair the immune recognition mediated by CD8+ T cells. Although NKG2DL expression can also contribute to the recognition by NK cells, the elimination and lysis of AML cells is ultimately dependent on the balance between all activating and inhibitory signals. In patients with NK cells, which do not recognize AML cells, blockage of anti-NKG2A receptor could be used as strategy to enhance the elimination of AML cells in a NKG2D-dependent manner. 
DISCUSSION
The NKG2D-NKG2DL system is involved in the innate and adaptive immune response, and has an important role in the immunosurveillance of cancer cells. Although MICA/MICB and ULBPs may be expressed in healthy cells, 36, 37 this does not normally occur under non-pathological circumstances. In response to cell stress such as infection or cancer, NKG2DL can be upregulated to promote immune recognition of tumor cells. 38 However, NKG2DL can be downregulated in tumor cells by various mechanisms, helping these cells evade the immune system. 39 Thus, current therapeutic strategies aim to induce NKG2DL expression to facilitate immune recognition. In this study, we show that epigenetic mechanisms, such as DNA methylation, may contribute to the absence of NKG2DL expression in tumor cells.
NKG2DL expression was highly heterogeneous among the tumor cell lines analyzed, suggesting that while some cells may be susceptible to lysis exerted by NKG2D-expressing cytotoxic cells, others may escape the immune system. MICA and MICB were the most commonly expressed ligands, whereas ULBPs expression was highly restricted, except in colon cancer cell lines. Moreover, NKG2DL was expressed at lower levels in AML cells than in other cell types. NKG2DL expression in AML has been analyzed in-depth, but some controversies remain. Some authors reported null or low levels of NKG2DL expression in AML patients, 40, 41 while others showed that at least one NKG2DL is expressed in AML blast. 42 Moreover, the expression patterns of NKG2DL are highly variable not only among AML patients but also in ALL patients, in whom MICA is the most frequent ligand. 43 By contrast, the relevance of NKG2DL expression is widely accepted in epithelial tumors. High levels of MICA and ULBP1 expression are associated with tumor progression in HCC patients. 44 NKG2DL are strongly expressed in breast cancer patients, where their levels are associated with the prognosis of the disease. 45 We found that expression of two or more ligands is more frequent in solid than in hematological tumors in which NKG2DL expression is highly restricted and thereby contributes to immune evasion.
The lower level of NKG2DL transcription found, especially in cells from hematological tumors, prompted us to examine whether aberrant DNA methylation patterns in these genes could contribute to the absence of expression in tumors. To this end, we used the bisulfite pyrosequencing technique, with which the level of DNA methylation for each CpG dinucleotide can be quantified. All NKG2DL were hypermethylated in some cell lines, except MICB, which showed only partial DNA methylation. Of all the cancer cell lines (AML, ALL, HCC, breast and colon cancer), the highest frequency of methylated NKG2DL was observed in AML cells. DNA methylation levels for NKG2DL were inversely correlated with transcription levels.
During tumor development, the mechanisms controlling DNA methylation can be dysregulated, allowing a decrease of DNA methylation levels mainly in oncogenes or a higher level of methylation in CpG dinucleotides of tumor-suppressor genes. 46 In blood cell subsets from healthy donors, NKG2DL expression has been found in B cells, monocytes and granulocytes, but not in NK or T cells. 40 Consistent with this, we found no methylation of NKG2DL in any of these cell subsets of healthy controls. Interestingly, high levels of DNA methylation for all NKG2DL were detected in AML patients. Thirty-six (59%) of the patients analyzed showed at least one methylated ligand, ULBP2 being the most frequent. The combination of methylated NKG2DL varied substantially among patients in accordance with the previously reported high degree of variability of expression of these ligands. 43 This result suggests that NKG2DL can be aberrantly methylated during tumor progression, contributing to their downregulation in AML. The propensity for NKG2DL methylation during hematopoietic maturation remains poorly understood because NKG2DL are unmethylated in CD34 + stem cells and remain unmethylated during hematopoietic differentiation and in mature blood cell subsets. 47 Malignant transformation may involve selection of cells with aberrant methylation of NKG2DL that prevents their expression at the cell surface.
In colon cancer, NKG2DL expression is upregulated in the earliest stages of the diseases and consequently further downregulated, giving a poor prognosis of the disease. 48 Methylation of ULBP2 and ULBP3 has previously been reported in colon cancer cell lines. 35, 49 However, we found that all the ligands analyzed (MICA, MICB, ULBP1, ULBP2 and ULBP3) were unmethylated and highly expressed in colon cancer cell lines. Moreover, analysis of the NKG2DL methylation status in colon cancer patients showed that both normal and tumor tissues from colon cancer patients were hypomethylated independently of the tumor stage. The different promoter region analyzed, in our case closely located to the transcription start site, could account for the observed difference between both studies. Therefore, our data suggest that DNA methylation changes at the NKG2DL promoter could be more prevalent in AML than in solid tumors such as colon cancer.
Absence or a low level of expression of NKG2DL in tumor cells hinders recognition by NKG2D-expressing cytotoxic cells, promoting immunoescape. Therefore, current therapeutic strategies aim to enhance NKG2DL expression on the surface of tumor cells to promote their lysis and to prevent tumor development. In this study, we found that treatment with demethylating agents (5azaC or DAC) increased NKG2DL transcription in AML, HCC and breast cancer cells. However, NKG2DL were enhanced on the cell surface only in AML cells, leading to greater recognition and lysis by cytotoxic NK cells. These results suggest that DNA demethylation could contribute to the recognition and lysis of tumor cells by the immune system. Epigenetic drugs such as 5azaC and DAC have been approved by the US Food and Drug Administration as alternatives to traditional therapies (best supportive care or ara-C) in AML patients. The advantage of these agents over traditional treatments is the better outcome they provide for patients, possibly as a consequence of the increased immune recognition of the tumor. 50, 51 However, the exact mechanisms and the identity of targets where they act are largely unknown at present.
These hypomethylating reagents have opposite effects in NK cell activity. Although azacytidine impairs cytotoxicity, decitabine enhances this effect. 52 Moreover, it should be noted that target susceptibility to NK-mediated lysis does not exclusively depend on the interaction between NKG2D and its ligands. NK cells are regulated by several inhibitory receptors (KIRs, ILT2 and NKG2A) and activating receptors (NKG2D, NKp30, NKp46, NKp44, DNAM-1 and 2B4). 53 The variability in the expression of these receptors will determine the susceptibility of AML blast to NK-mediated lysis. NK cells from AML patients have an abnormal phenotype featuring downregulation of the NCRs (NKp46, NKp30 and NKp44) and DNAM-1 receptors, and upregulation of the inhibitory receptor NKG2A and KIR2DL2, which contributes to tumor evasion. 40, [54] [55] [56] [57] So, new anti-leukemic therapies focus on the transfusion of NK cells from donors with identical HLA-I in order to promote the in vivo expansion of NK cells and their cytotoxicity to AML cells. 58, 59 Therefore, although our findings demonstrate that hypomethylating agents promote NKG2DL expression in AML cells, lysis of methylated-and unmethylated-NKG2DL cell lines by NK cells will depend on the global balance between activating and inhibitory signals. Treatment of AML patients with demethylating agents could modify the expression of these receptors and their ligands, altering the lytic ability of NK cells. In this way, it have been shown that lack of DNMTs by itself or in combination with mitogen-activated protein kinase/extracellular signal-regulated kinases 1/2 inhibitors, not only increases the expression of the ULBP2 ligand but also HLA-class I molecules. Consequently, HLAclass I molecules overexpression could be counteracting the immune recognition mediated by NKG2D-NKG2DL interaction. 35 Further studies are needed to identify these changes of expression and their consequences for the recognition and elimination of AML cells. On the other hand, we found that AML recognition by CD8 + T lymphocytes is dependent on NKG2DL methylation status suggesting that aberrant DNA methylation has an important role in the immune evasion of AML cells.
In summary, we showed that the absence of NKG2DL expression from AML tumor cells could be due to the aberrant DNA methylation of these genes during tumor progression. This is the first time that aberrant hypermethylation of NKG2DL has been reported in AML patients. Quantification of the level of DNA methylation by pyrosequencing may be useful as a marker of tumor evolution in AML. Reactivation of epigenetically silenced NKG2DL expression by hypomethylating agents could facilitate the immune recognition and lysis of AML blast. Additional studies are needed to understand the effect of these demethylating treatments on other NK cells receptors and their ligands, by which the elimination of tumor cells can be promoted. 
MATERIALS AND METHODS
Cell lines and treatments with DNMTi
Cell lines of AML (NB4, HL60, HEL-R, KG1A, MV4;11, MOLM-13 and KASUMI-1), ALL (RS411, KOPN-8, JURKAT and REH), HCC (HUH7, ALEX, SNU354 and SNU368), breast cancer (CAMA-1, MCF-7, T47D, MDA-MB-157 and MDA-MB-436) and colon cancer (SW480, SW620, HCT166, HT29 and RKO) were maintained in RPMI-1640 medium plus 10% heat-inactivated serum. Polymorphonuclear cells were isolated from the hemolyzed pellet after being subjected to a standard Ficoll (Lymphoprep) gradient. CD14 + monocytes were isolated by sorting after staining with anti-CD14fluorescein isothiocyanate (FITC) antibody (Biolegend, San Diego, CA, USA). CD4 + , CD8 + T cells and NK cells sub-populations were isolated by negative selection using magnetic microbeads (Invitrogen, Carlsbad, CA, USA). The purity of isolated cells was always 495%. For cytotoxic experiments, the NKL (derived from NK cells) and C1R (human B-cell lymphoma) cell lines were grown in RPMI-1640 medium plus 10% heat-inactivated fetal bovine serum and 100 U ml -1 of streptomycin-penicillin. The NKL effector cells were supplemented with 100 U/interleukin-2 (Novartis, Basel, Switzerland). C1R-MICA*004 transfectants were maintained in complete medium supplemented with hygromycin B at 800 μg ml -1 (Invitrogen).
Tumor cell lines were cultured at a density of 0.5 × 10 6 cells ml -1 with complete media supplemented with 5azaC (2.5 or 10 μM) or DAC (1 or 5 μM) (Sigma-Aldrich, St Louis, MO, USA) for 72 h. Cell viability was determined by staining with 7AAD (Immunostep Inc., Salamanca, Spain).
Patients
Blood samples were obtained from 60 AML patients (35 males and 25 females) from Reina Sofia Hospital (Córdoba, Spain) who had been diagnosed with de novo non-M3 AML during 2000-2008. The diagnosis was made according to the morphological and cytochemical criteria of the French-American-British classification. Twenty-five healthy adult blood donors, obtained from the Blood Transfusion Center, Oviedo, Spain, were used as controls. In addition, a set of 44 paired adjacent normal and tumor tissues from colorectal cancer patients (31 males and 13 females) obtained from Puerto del Hierro Hospital (Madrid, Spain) were included in this study. All patients and healthy donors gave their written informed consent, in adherence to the Principles of the Declaration of Helsinki and the guidelines of the local ethics committee. Supplementary Tables 1 and 2 summarize the patients' characteristics.
Bisulfite conversion and DNA sequencing
DNA was purified using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA) and modified with bisulfate using the EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA, USA). Converted DNA was amplified using specific primers ( Supplementary Table 1 ) and PCR products were cloned into the pGEM-T Easy Vector System II (Promega, Madison, WI, USA) and 10 independent clones were sequenced for each gene.
Bisulfite pyrosequencing
Bisulfite-modified DNA was amplified by PCR with specific biotinylated primers designed using PyroMark Assay Design Software 2.0 (Qiagen). Details of primers are available from the authors on request. Briefly, sequencing primers were designed to hybridize with CpG-free sites to ensure methylation-independent amplification. Pyrosequencing was performed with the PyroMark Q24 System version 2.0.6 (Qiagen), following the instructions in the PyroMark Gold Q24 Reagents Handbook (Qiagen). Methylation levels were quantified using PyroMark Q24 Software 2.0 (Qiagen).
Flow cytometry analysis
Cells were stained with the human mAb specific for each NKG2DL (R&D Systems, Minneapolis, MN, USA) and were then incubated with FITCconjugated goat anti-mouse immunoglobulin G (eBioscience, San Diego, CA, USA) and analyzed on a BD FACScalibur Cytometer using the CellQuest Pro Software package (Becton Dickinson, Sparks, MD, USA). The specific fluorescence index was calculated by dividing mean fluorescence obtained with the respective specific mAb by that of the secondary antibody. Cell viability was determined by staining with 7AAD (Immunostep Inc.).
Quantitative real-time PCR analysis
RNA was purified using NucleoSpin RNA II (Macherey-Nagel, Duren, Germany) and reverse-transcribed using the iScript cDNA Synthesis Kit (Bio-Rad, Berkeley, CA, USA). NKG2DL were amplified with specific primers for NKG2DL (Qiagen) using iQ SYBR Green Super Mix (Bio-Rad) for 40 cycles in the MyiQ Single Color Real-Time PCR Detection System (Bio-Rad). Values were adjusted using glyceraldehyde 3-phosphate dehydrogenase as the endogenous control and all samples were run in triplicate. Relative mRNA abundance was determined by the 2 − ΔCt method (ΔCt: Ct gene test-Ct endogenous control).
Cytotoxicity assay
Cytotoxicity was assayed using the PKH67 Green Fluorescent Cell Linker kit (Sigma-Aldrich) and by flow cytometry, as previously described. 53 We used the NKL cell line as effector cells because it is broadly suitable for studies based on the NKG2D-NKG2DL interaction, given the high levels of NKG2D expression. HL60, NB4 and KG1A cells were treated beforehand with dimethylsulphoxide, 5azaC (10 μM) or DAC (5 μM) for 72 h and further co-cultured with the NKL effector cells for 4 h at 37°C. After that, cells were stained with 5 μl of 7AAD and analyzed by flow cytometry. Target cells incubated in the absence of effector cells were used as a negative control. Percentage specific lysis was calculated using the formula: % NK-specific lysis = 100 × [(% 7AAD staining of sample-% 7AAD staining of negative control)/(100-% 7AAD staining of negative control)]. For blocking experiments, NKL cells were incubated beforehand with 10 μg ml -1 anti-human NKG2D blocking mAb (Biolegend) for 1 h at 4°C.
IFN-γ production and degranulation assay
For intracellular IFN-γ analysis, NKL cells were co-cultured with AML cell lines previously treated or not treated with the demethylating agents (5azaC at 10 μM and DAC at 5 μM for 72 h) at E:T ratio 2:1. After 1 h, brefeldin A (10 μg ml -1 , eBioscience) was added for an additional 5 h, and cells were stained with anti-CD16-APC, fixed and permeabilized for intracellular staining with anti-INFγ-FITC antibody (Biolegend) for 30 min. Cells were washed and analyzed by flow cytometry.
Degranulation of NKL cells and isolated NK and CD8+ T cells from healthy donors was assessed by flow cytometry analysis of CD107a lysosome-associated membrane protein-1 expression. AML cell lines were incubated with the effector cells at an E:T ratio of 1:1. CD107a-FITC antibody was added directly to the wells and, after 1 h of culture, monesin (6 μg ml -1 , eBioscience) was added for an additional 5 h. Cells were then stained with CD8-PE, CD3-PerCP and CD16-APC antibodies (all from Biolegend) and analyzed by flow cytometry. In blocking experiments, effector cells were incubated beforehand with anti-NKG2D mAb (Biolegend), anti-NKG2A mAb (Biolegend), and anti-2B4 mAb (eBioscience) at 10 μg ml -1 or anti-HLA-class I mAb supernatant for 1 h at 4°C.
Statistical analysis
Statistical tests were carried out with SPSS 15.0 (Chicago, IL, USA). Values of Po0.05 were considered to be statistically significant.
